Related Experiment Video
Updated: May 14, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia]
1Department of Urology, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, China. yuanrunqiang@yeah.net
Abstract:
Tadalafil, as a selective phosphodiesterase type 5 inhibitor (PDE5I), has revolutionized the treatment of erectile dysfunction (ED) in men. Conventional management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), which is highly complex and likely multifactorial, is associated with unwanted side effects. Innovative once-daily tadalafil regimen is effective in treating the signs and symptoms of BPH. In recent trials in men with BPH, tadalafil significantly improved total IPSS over the initial 12 weeks of medication. Moreover, tadalafil is effective in treating both ED and the signs and symptoms of BPH. In this study, we review the current state of this new management strategy for LUTS secondary to BPH, highlighting the published reports on the efficacy and tolerability of tadalafil.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Urinary Tract Calculi III: Medical Management
Anatomy of the Genitourinary System II: Bladder and Urethra
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
